Viron to Present Data from Phase II Trial at American Heart Association Conference
LONDON, ON, Nov. 11 /PRNewswire/ -- Viron Therapeutics Inc., a
biopharmaceutical company pioneering the development of viral
protein therapeutics, announced today that the Company's research
collaborator, Dr. Jean-Claude Tardif, Director of the Research
Center at the Montreal Heart Institute, will present data from a
Phase IIa clinical trial evaluating VT-111 at the American Heart
Association (AHA) Scientific Sessions 2009 conference. The
conference will take place in Orlando, Florida from November 14 to
18, 2009.
The presentation entitled, "Viral Anti-inflammatory Treatment of
Unstable Coronary Syndromes: The VT-111 Acute Coronary Syndrome
Trial," will disclose recent results from a Phase IIa trial
evaluating VT-111, a serine protein inhibitor, in patients with
Acute Coronary Syndromes receiving coronary stents. Dr. Tardif's
presentation is scheduled for Wednesday, November 18, 2009, at
11:00 AM (ET) in Room W304gh of the Orange County Convention
Center. A copy of the presentation will be available after the
conference on Viron's website, www.vironinc.com.
About VT-111
VT-111, an immune-modulating protein therapeutic, is the world's
first viral-derived human therapeutic. It is a novel inhibitor of
the monocyte/macrophage influx to sites of injury and has
demonstrated potent efficacy in preclinical models of acute injury
in which inflammation plays a key role. VT-111 recently completed a
Phase IIa trial of 48 patients with Acute Coronary Syndromes
receiving coronary stents. In addition to advancing the
cardiovascular program with a partner, Viron is moving to conduct
appropriate preclinical studies prior to a clinical program to
evaluate the effects of VT-111 in solid organ
transplantation.
About Viron Therapeutics Inc. (www.vironinc.com)
Viron is a biopharmaceutical company pioneering the development
of pathogen proteins, a revolutionary new class of drugs. These
drugs leverage strategies evolved by pathogens to inactivate key
targets in the human immune system. The Company's proprietary
PROSPECT(TM) technology, PROtein Screen for Pathogen-Evolved
Combination Therapeutics, is a platform for the discovery of new
immune-modulating protein therapeutics. Its significant pipeline of
products target critical pathways that have broad application to
immune and inflammatory based diseases such as cardiovascular
disease and rheumatoid arthritis. VT-111, the Company's lead
compound, is in development to treat Acute Coronary Syndromes and
solid organ transplant rejection.
Source: Viron Therapeutics Inc.
CONTACT: Viron Therapeutics Inc., Kevin Sullivan, Vice
President,
Business Development, Phone: (519) 858-5120, Fax: (519) 858-5103,
E-mail:
ksullivan@vironinc.com,
www.vironinc.com; Investor Relations, Ross Marshall,
The Equicom Group Inc., Phone: (416) 815-0700 (Ext. 238), Fax:
(416) 815-0080,
E-mail: rmarshall@equicomgroup.com
Posted: November 2009
